CERo Therapeutics Holdings Inc (NASDAQ: CERO) is -92.55% lower on its value in year-to-date trading and has touched a low of $0.43 and a high of $102.00 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CERO stock was last observed hovering at around $0.45 in the last trading session, with the day’s loss setting it 0.0%.
Currently trading at $0.45, the stock is -23.88% and -36.78% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.04 million and changing 0.29% at the moment leaves the stock -92.98% off its SMA200. CERO registered -99.54% loss for a year compared to 6-month loss of -96.96%. The firm has a 50-day simple moving average (SMA 50) of $0.7168 and a 200-day simple moving average (SMA200) of $6.43807.
The stock witnessed a -49.91% gain in the last 1 month and extending the period to 3 months gives it a -68.98%, and is -15.72% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.62% over the week and 5.54% over the month.
Distance from 52-week low is 3.40% and -99.56% from its 52-week high. The company has generated returns on investments over the last 12 months (-5432.19%).
The EPS is expected to grow by 73.05% this year.
CERo Therapeutics Holdings Inc (CERO) Top Institutional Holders
17.0 institutions hold shares in CERo Therapeutics Holdings Inc (CERO), with institutional investors hold 13.67% of the company’s shares. The shares outstanding are 7.72M, and float is at 5.44M with Short Float at 11.96%. Institutions hold 11.77% of the Float.
CERo Therapeutics Holdings Inc (CERO) Insider Activity
The most recent transaction is an insider sale by YK Bioventures Opportunities G, the company’s 10% Owner. SEC filings show that YK Bioventures Opportunities G sold 2,998,908 shares of the company’s common stock on Dec 13 ’24 at a price of $0.06 per share for a total of $0.18 million. Following the sale, the insider now owns 13.01 million shares.
CERo Therapeutics Holdings Inc disclosed in a document filed with the SEC on Dec 12 ’24 that YK Bioventures Opportunities G (10% Owner) sold a total of 1,614,541 shares of the company’s common stock. The trade occurred on Dec 12 ’24 and was made at $0.07 per share for $0.11 million. Following the transaction, the insider now directly holds 16.0 million shares of the CERO stock.
Still, SEC filings show that on Dec 11 ’24, YK Bioventures Opportunities G (10% Owner) disposed off 1,343,801 shares at an average price of $0.08 for $0.11 million. The insider now directly holds 17,618,618 shares of CERo Therapeutics Holdings Inc (CERO).
